drugset / Trial / NCT06499350
A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to learn the safety, tolerability, pharmacokinetic characteristics and efficacy of FC084CSA in combination with Tislelizumab in patients with advanced malignant solid tumors.
Timeline
- Start
- 2024-11-13
- Primary completion
- 2026-07-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FC084CSA | Unknown | — | — |
| Subject | Tislelizumab | Monoclonal antibody | — | — |